Interferon Alfa-2b · Intron A, SCH-30500

What is Interferon Alfa-2b?

Interferon Alfa-2b is a non-glycosylated recombinant interferon that binds to cell-surface interferon alpha receptors, triggering antiviral, antiproliferative, and immune-modulating effects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Intron A, SCH-30500, Bioferon

Drug type

Recombinant protein

Targets

Interferon alpha receptor (IFNAR1)

Mechanism

Immune activation, directed at Interferon alpha receptor (IFNAR1)

Pathways

antiviral response, antiproliferative signaling, immune modulation

Therapy area

Oncology

Developer

Schering

In trials of

AIM

FDA status

Approved as Intron A (June 4, 1986), BLA103132 · FDA label

UNII

43K1W2T1M6

✅ FDA-approved uses

• Hairy Cell Leukemia
• Malignant Melanoma
• Follicular Non-Hodgkin's Lymphoma
• Condylomata Acuminata
• AIDS-Related Kaposi's Sarcoma
• Chronic Hepatitis C

From the indications section of the FDA label (version of Jan 23, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian CancerProstate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8

Other drugs acting on IFNAR1

Sources

• FDA label Intron A (2024-01-23), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT07634094

Updated Oct 3, 2026.